Drug major Jubilant Life Sciences has received a nod from the US Food and Drugs Administration (FDA) to market a generic diuretic medicine, the company said on Friday.
The Spironolactone tablets (25 mg, 50 mg and 100 mg), which received the abbreviated new drug application approval, is the generic version of GD Searle’s Aldactone. It is used to treat fluid retention in the body caused by conditions such as congestive heart failure and cirrhosis of the liver.
Jubilant said it will launch this product, which has a market size of $87 million a year, in the first quarter of the fiscal year 2015-16.